MX2022005661A - Agonistas del receptor npy2. - Google Patents

Agonistas del receptor npy2.

Info

Publication number
MX2022005661A
MX2022005661A MX2022005661A MX2022005661A MX2022005661A MX 2022005661 A MX2022005661 A MX 2022005661A MX 2022005661 A MX2022005661 A MX 2022005661A MX 2022005661 A MX2022005661 A MX 2022005661A MX 2022005661 A MX2022005661 A MX 2022005661A
Authority
MX
Mexico
Prior art keywords
receptor agonists
analogues
npy2 receptor
relates
npy2
Prior art date
Application number
MX2022005661A
Other languages
English (en)
Inventor
Stefan Peters
Peter Wilhelm Haebel
Albert Brennauer
Charlotte Stahl Madsen
Søren Ljungberg Pedersen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022005661A publication Critical patent/MX2022005661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de vida media. Los análogos de la invención son solubles a alrededor de pH 6 y 7. La invención también se refiere a composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos.
MX2022005661A 2019-11-11 2020-11-09 Agonistas del receptor npy2. MX2022005661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
MX2022005661A true MX2022005661A (es) 2022-09-07

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005661A MX2022005661A (es) 2019-11-11 2020-11-09 Agonistas del receptor npy2.

Country Status (18)

Country Link
US (2) US20210139548A1 (es)
EP (1) EP4058047A1 (es)
JP (1) JP2023500895A (es)
KR (1) KR20220100925A (es)
CN (1) CN114641303A (es)
AR (1) AR120440A1 (es)
AU (1) AU2020384729A1 (es)
CA (1) CA3156452A1 (es)
CL (1) CL2022001227A1 (es)
CO (1) CO2022006046A2 (es)
CR (1) CR20220206A (es)
EC (1) ECSP22037660A (es)
IL (1) IL292601A (es)
JO (1) JOP20220110A1 (es)
MX (1) MX2022005661A (es)
PE (1) PE20221168A1 (es)
TW (1) TW202134263A (es)
WO (1) WO2021094259A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300239A (en) * 2020-08-07 2023-03-01 Boehringer Ingelheim Int Soluble NPY2 receptor agonists
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174115B (zh) 2004-02-11 2014-05-14 安米林药品有限责任公司 具有可选择特性的杂合多肽
AU2005316524B2 (en) 2004-12-13 2012-01-12 Amylin Pharmaceuticals, Llc Pancreatic Polypeptide Family motifs, polypeptides and methods comprising the same
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
AU2007360979B2 (en) 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
AU2008365559B2 (en) 2008-12-15 2016-02-25 Zealand Pharma A/S Glucagon analogues
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
JP2013505221A (ja) 2009-09-18 2013-02-14 ノヴォ ノルディスク アー／エス 長時間作用性ｙ２受容体アゴニスト
CN102905722A (zh) 2009-11-13 2013-01-30 诺沃—诺迪斯克有限公司 长效y2受体激动剂
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN103068841A (zh) 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
EP2718315B1 (en) 2011-06-10 2017-12-27 Novo Nordisk A/S Pramlintide derivatives
PE20142113A1 (es) 2011-12-23 2014-12-03 Zealand Pharma As Analogos de glucagon
SG11201407137PA (en) 2012-05-03 2014-11-27 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014178018A1 (en) 2013-05-02 2014-11-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
BR112016008115B1 (pt) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
HUE037663T2 (hu) 2013-11-14 2018-09-28 Keybioscience Ag Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
EP3068421B1 (en) * 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof
AU2016232218B2 (en) 2015-03-18 2020-09-10 Boehringer Ingelheim International Gmbh Amylin analogues
ES2763329T3 (es) 2015-04-16 2020-05-28 Zealand Pharma As Análogo de glucagón acilado
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
CN116063453A (zh) 2015-12-31 2023-05-05 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TW202208410A (zh) 2018-11-01 2022-03-01 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法

Also Published As

Publication number Publication date
US20210139548A1 (en) 2021-05-13
AR120440A1 (es) 2022-02-16
TW202134263A (zh) 2021-09-16
PE20221168A1 (es) 2022-07-25
IL292601A (en) 2022-07-01
JP2023500895A (ja) 2023-01-11
CA3156452A1 (en) 2021-05-20
ECSP22037660A (es) 2022-06-30
JOP20220110A1 (ar) 2023-01-30
CO2022006046A2 (es) 2022-05-20
KR20220100925A (ko) 2022-07-18
AU2020384729A1 (en) 2022-04-14
CL2022001227A1 (es) 2023-02-03
EP4058047A1 (en) 2022-09-21
WO2021094259A1 (en) 2021-05-20
CR20220206A (es) 2022-06-16
CN114641303A (zh) 2022-06-17
US20230340039A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
CR20230074A (es) Agonistas del receptor npy2 solubles
PH12018502465A1 (en) Mic-1 compounds and use thereof
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MY187047A (en) Selective pyy compounds and uses thereof
JOP20220110A1 (ar) ناهضات مستقبل npy2
NZ743487A (en) Controlled-release cnp agonists with increased nep stability
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
NZ743488A (en) Controlled-release cnp agonists with low initial npr-b activity
NZ743489A (en) Controlled-release cnp agonists with low npr-c binding
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2022001719A (es) Formulaciones de conjugados de benzazepina y usos de las mismas.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
PH12020551659A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
WO2020109526A3 (en) Oxyntomodulin peptide analog formulations
EA202192475A1 (ru) Способ получения стабильных пептидных составов
BR112022006297A2 (pt) Agonistas de receptor de npy2
MX2021015930A (es) Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1.
CR20220591A (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
RS20170169A1 (sr) Poboljšana rekonstituisana kompozicija sufraktanta koja sadrži analoge sufraktanta proteina b (sp-b) i surfaktanta proteina c (sp-c)